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In the state of the art evaluation of nutritional therapy on tumor
development, growth and vascularization requires tedious and
expensive in vivo assays in which a signiﬁcant number of animals
undergo invasive treatments. Therefore, new alternative methods
to avoid animal suffering and sacriﬁce are welcome. This review
presents a rapid and low-cost method of experimental radio/
chemotherapy in tumor xenografted chicken chorioallantoic
membrane (CAM), which may contribute to implement the 3R
principle (Reduce, Reﬁne, Replace). Advantages and limitations of
the CAM as an experimental model in cancer research are dis-
cussed. Improving the CAM model by using tumor spheroid
grafting and positron emission and computed tomography imag-
ing would help to overcome the drawbacks of poor tumor grafting
efﬁciency and restrained 2-D tumor growth measurement to the
CAM surface. Such a simple, reliable, reproducible and quantitative
method for obtaining doseeresponse analysis and estimating
treatment schedule (i.e. type, route, dose and timing) would pro-
vide an alternative to the time-consuming and expensive evalua-
tion step in animals before initiating clinical trials.
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Evaluation of new nutritional therapies on tumor development and growth requires preclinical
studies focusing on physical, chemical, pharmacodynamic, pharmacokinetic and toxicological analyses.
Part of them can be conducted in vitro, but they have to be validated in an animal model before
initiating clinical trials.
1.2. Needs for an alternative to animal experimentation
Dose-response determination of the treatment relevance, toxicity and schedule (i.e. doses, route
and timing) requires a substantial number of animals undergoing experiments of severity degrees 2 to
3. In 2011, 1,105,921 animals were used in cancer research (17.8% of all animals used for studies of
diseases) according to the report of the European Statistics Commission on the number of animals used
for experimental and other scientiﬁc purposes in the Member States of the United Europe [1].
Therefore, new alternative methods to avoid animal suffering and sacriﬁce and implement the 3R
principle (Reduce, Reﬁne, Replace) are welcome. We present here a transition method between in vitro
and in vivo experiments that allows to quickly assess the treatment feasibility and to provide an es-
timate therapeutic dose before further in vivo evaluation.
1.3. The CAM model
The chick embryo chorioallantoic membrane (CAM) model is used in the pharmaceutical research
for the evaluation of drug delivery systems, because this in ovomethod is close to the in vivo conditions,
cheap (egg purchasing and maintenance), simple (extra-embryonic, highly vascularized) and rapid to
implement [2]. Moreover, utilization of the CAM model does not require tedious administrative pro-
cedures for obtaining ethics committee approval for animal experimentation, because the chick em-
bryo is not considered as living animals until Embryo Development Days (EDD) 17 in most countries.
This particular feature allows for rapid adaptations of the experimental protocol according to the re-
sults obtained. In total, the chicken embryo takes 21 days from the beginning of incubation to the
hatching. CAM appears between EDD 4 and 5. This transparent and highly vascularized membrane in
direct contact with the eggshell is the respiratory system allowing embryo to gas exchange. This is the
reason why CAM is widely used to study angiogenesis, but also wound healing [3], tissue engineering
[4], biomaterials [5], implants [6] and biosensors [7].
1.4. The CAM model in cancer research
One of the advantages of the CAM model is the lack of mature immunity (it lacks both B and T cell-
mediated immune functions) up to EDD 18 when the chicken embryo becomes immunocompetent.
However, the presence of T and B cells can already be detected at EDD 11 and 12. This feature allows the
xenografting of human tumors on the CAM surface. Thus, the pharmaceutical effects of new drug
formulation can be evaluated not only on CAM vasculature, but also on embryo development and
xenografted tumors.
1.5. Advantages of the CAM compared to mammalian models
Mammalian models are broadly used for preclinical evaluation of drug formulation but those
models are expensive, time-consuming and associated with administrative burden with respect to
ethical and legal aspects. The CAM model allows to overcome these tedious steps until EDD 17 and to
obtain tumors more rapidly and at low cost. Indeed, xenografted tumors take only three to ﬁve days to
grow after cancer cell grafting and are visible to the naked eye, whereas tumors can take much more
time to develop in mammalian models [8]. The CAMmodel is increasingly used to study the migrating
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breast [13], prostate [14] and colorectal tumors [15,16]. The CAM model is particularly relevant for
studying metastasis, because the majority of cancer cells (>80%) extravasate 1e3 days after their
intravenous injection and migrate through the mesenchyme to attach to arterioles in distant organs
[17]. Thus, the CAM model is a good alternative to test new nutritional therapies in cancer research.
Moreover, the U.S. Food and Drug Administration (FDA) has approved products pre-clinically evaluated
in the CAM model and released a FDA guidance for industry in 2006 for the treatment of chronic
cutaneous ulcer and burn wounds [18].
1.6. Limitations of the CAM model
The main limitation of the use of the CAM model in cancer research is the reproducibility of the
tumor grafting from one egg to another. The grafting rate and tumor size are not always high and
uniform within an experiment. Moreover, the CAM does not tolerate well changes in pH, osmolarity,
keratinization and oxygen tension, which can occur when the shell is opened or sealed [19]. Actually,
successful grafting depends in great part on the operator's skill and the type of cancer cell line used.
Moreover, despite the immaturity of the chick immune system, non-speciﬁc inﬂammatory reaction can
occur as a result of the tumor grafting and induce unspeciﬁc angiogenesis with inﬁltrating leukocytes
[20]. Thus, tumor neovascularization can hardly be distinguishable from unspeciﬁc angiogenesis,
especially as the tumor is grafted at the intersection of existing blood vessels whose vascular density
and course within the CAM mesenchyme change during embryo development [21]. One way to avoid
non-speciﬁc inﬂammatory response is to graft the tumor just at the onset of CAM development whilst
the immune system of the embryo is still immature and to document vessel formation by sequential
camerawork [21]. However, the time between the grafting and chick hatching (8e10 days) is short and
the interactions between immune and cancer cells cannot be evaluated [10]. Moreover, the current
methods of investigation in the CAM model are often based on score measurements of visual or
microscopic observations. The results are relatively subjective and a high inter-individual variability in
the vessel counting or tumor size measurement can be noticed from one operator to another. It is
important to always perform experiments on the same EDD, because CAM development is charac-
terized by rapid morphological changes [22]. In cancer research, the main drawbacks are therefore the
variability in tumor grafting and the limitation of 2-D tumor growth measurement at the CAM surface,
whereas the tumor often grows through the CAM mesenchyme.
1.7. Improving the CAM model for studying treatment effects on tumor growth
Some improvements can be made to make the CAM model more attractive for cancer research, so
that it can be used more readily to evaluate the effect of different treatments on tumor development,
growth and vascularization. We recently developed a 3-D imaging of the tumors xenografted on the
CAM, using positron emission and computed tomography (microPET/CT). The reproducibility of tumor
grafting was improved by implanting tumor spheroids in the CAM. Such an innovative approach would
provide an alternative to the time-consuming and expensive evaluation of new anticancer treatments
in animals before initiating clinical trials (Fig. 1).
2. Methodological approach
2.1. Tumor spheroid production
Currently, the most commonly used method in cancer research is the 2-D monolayer cell culture,
where cells nonspeciﬁcally adhere to rigid plastic well plates and lose the gene expression proﬁle and
morphology present in real tumors. To better mimic physiological conditions, methods of multicellular
spheroid production have been developed, using 3-D culturewhere cells are suspended in extracellular
matrix, which provides ligands and malleable surface. It has been demonstrated that the addition of
extracellular matrix proteins promotes cellecell bonds, cell aggregation and spheroid formation for
cancer cell lines that were previously considered incompatible with such culture condition [23]. To
Fig. 1. Description of the different steps to evaluate the impact of nutritional therapies on the growth and vascularization of tumor spheroids xenografted in the CAM, using microPET/CT. 1)
Cancer cell culture in 96-well spheroid formation plate with extracellular matrix; 2) Tumor spheroid grafting in the CAM; 3) Chemotherapy using intravenous injections with/without nutritional
therapy and/or radiotherapy using SRT100 Topex irradiator; 4) Evaluation of tumor vascularization using ﬂuorescence microscopy; 5) Evaluation of tumor growth ([18F]FDG) and angiogenesis
(VEGF, integrins, a2b3 or a5b1) using microPET/CT imaging.
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Y.M. Dupertuis et al. / Clinical Nutrition Experimental 2 (2015) 9e17 13produce tumor spheroids for the CAM model, we use a commercial kit and proceed according to the
manufacturer's instructions (Cultrex® 3-D Spheroid Cell, Trevigen, Gaithersburg). Human cancer cells
are cultured in standard cell culture medium supplemented with 10% heat-inactivated fetal bovine
serum and 0.1 g/L penicillin-streptomycin. Cells are kept at 37 C in a humidiﬁed air containing 5% CO2
and maintained in exponential growth phase. For the production of one tumor spheroid/well, cells are
harvested, resuspended at a density of 3000 cells/50 mL/well in the extracellular matrix, and then
cultured for 48e72 h in a 96-well spheroid formation plate. The initial number of cells per wells and the
incubation time can be adjusted to monitor the tumor spheroid diameter. We recommend producing
tumor spheroids of at least 500 mm diameter to obtain well-to-well size uniformity and diffusion
gradients for pH, oxygen, nutrients and catabolites that will establish heterogeneous cell population
with proliferating cells at the spheroid surface, quiescent cells in the deeper layers and hypoxic cells in
the core [24]. This straightforward method can reproducibly allow generating tumor spheroids in high
quantities.
2.2. CAM preparation
CAM method implementation previously requires the purchase of a specially egg-dedicated incu-
bator and the possibility to order fertilized hen eggs from a pet supplier. Fertilized eggs are placed with
the narrow apex down and rotated 180 automatically every 6 h in the incubator at 37 C and 65%
relative humidity. From the ﬁrst EDD, eggs are candled and the embryo motility is checked for viability
every 24 h. The heartbeat and beak length can be measured with a digital egg monitor or with microCT
imaging to check for normal embryo development. At EDD 4, a 3-mm hole is drilled in the eggshell at
the narrow apex, cleaned with alcohol and protected with adhesive tape to avoid desiccation and
contamination. Eggs are incubated again but this time in stationarymode and narrow apex upwards. At
EDD 8, the hole is enlarged to 1e2 cm and CAM is scratched close to a blood vessel or around a junction
of several blood vessels. The tumor spheroid is deposited in this space, surrounded or not by a silicone
O-ring. After tumor spheroid deposit, the window on the eggshell is sealed with paraﬁlm and eggs are
returned to the incubator until EDD 11e12.
2.3. In ovo treatment
Depending on the tumor development, the treatment schedule can start around EDD 11e12. The
nutrient mixture can be inoculated (20e50 ml) directly into the cavity of the allantoic vesicle to reach
the tumor and thewhole vascular area uniformly [25]. It can also be administered topically by placing a
cotton wool soaked with the nutrient mixture to the CAM surface or intravenously, optionally in
combination with a chemotherapeutic drug. Intravenous administration is performed in the main
blood vessel of the CAM, through catheter or through a 3300 gauge needle at a volume of 20e50 ml. The
drug dose is adjusted according to the related antitumor and toxic effects on the chicken embryo. The
embryo survival rate is evaluated 24 h after the intravenous administration of the drug. Eggs can be
also treated by fractionated-dose radiotherapy according to current clinical practice, using X-ray
irradiator [15]. For example, we are using fractionated-doses of 2e6 Gy/day, using a SRT100 Topex
irradiator (Inc-30, 70,100 kV X-rays). However, radiation protection of the chick embryo is problematic
and dose calculation must take into account the eggshell attenuation. Dose homogeneity can be ob-
tained by alternative irradiation from opposite egg sides. The dose and fraction are adjusted according
to the related antitumor and toxic effects. A control dosimetry has to be performed by implantingmicro
dosimeters in the CAM. During the whole course of the experiment, the tumor surface is measured
repeatedly according to the following equation (Fig. 2):
Surface ¼ p x Length x Width
Eggs are checked daily andweighed at the treatment onset and end. Blood samples of ~0.5ml can be
collected from the CAM vein and stored at 80 C for further analyses. At the end of treatment, tumors
and healthy embryo organs can be weighed, mechanically and enzymatically disaggregated into a
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analyses, such as histology, immunohistochemistry or gene expression analysis using chicken Affy-
metrix microarrays. Drug content may also be analyzed after tissue lysis to have access to pharma-
cokinetic and biodistribution data.2.4. Evaluation of tumor angiogenesis
Tumor vascularization is usually evaluated using ﬂuorescence microscopy (angiography) after
intravenous injection of sulforhodamine. Tumor vasculature pictures are recorded at different times (1,
5, 10 min) after injection, using a CCD camera coupled with a ﬂuorescence microscope. The excitation
wavelength is set between 525 and 560 nm, using a dichroic mirror (570 nm) and an emitter HQ 610/
75 m ﬁlter (570e650 nm). To visualize the signal amplitude, two ﬁlters are added successively, the ﬁrst
one ND4 and the second ND8. Before injection, tissue autoﬂuorescence is recorded. Data acquisition
and measurement are done at 24, 48 and 72 h after treatment using a binocular microscope. Eggs can
be kept up to half an hour out of the incubator for observation. When they are placed back into the
incubator, the hole has to be covered with paraﬁlm.Fig. 2. Changes in tumor size in the CAM at 24 h, 48 h and 72 h after a new treatment (red) compared with shame treatment (blue).
Fluorescence microscopy after sulforhodamine injection indicates that the tumor surface growth tends to stop and even decrease
three days after treatment, compared to control.
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Protein expression involved in different mechanisms, such as cell proliferation, inﬂammation or
angiogenesis, can be assessed by immunohistochemical analyses of tumor and host tissue samples.
After treatment allowing speciﬁc antigene binding, tissue sections of 5 mM are incubated overnight in a
humidiﬁed chamber at 4 C with primary antibodies. It has to be noted that the availability of anti-
bodies to chicken tissues may preclude some analyses in the CAM model [26]. However, We use the
Universal LSAB-HRP system (Dako) to detect the signals according to manufacturer's instructions. To
determine protein expression in tissue sections, coloration is captured with a Mirax Scanner (Zeiss),
and positively stained cells of 10 different ﬁelds per tissue section are quantiﬁed using the Meta-
morph® imaging software.2.6. MicroPET/CT imaging in the CAM model
To date, only 2-D measurement of the tumor growth has been carried out in the CAM model. As
surface measurement do not take into account tumor invasion of the chorionic epithelium and
mesenchymal connective tissue below the CAM [27], we recently performed a 3-D evaluation of the
tumor growth using positron emission and computed tomography (microPET/CT) with the
commonly-used PET tracer [18F]-ﬂuorodeoxyglucose ([18F]FDG) and the contrast agent Telebrix-38
(Fig. 3). Alternatively, tumor vascularization can also be evaluated with VEGF or Integrin kits for
PET imaging. Eggs were ﬁxed on an animal bed for microPET/CT and injected intravenously with 3Fig. 3. MicroPET/CT imaging in the CAM model after an intravenous injection of 3 MBq [18F]FDG and 50 ml of Telebrix-38. After
MicroPET/CT acquisition, the tumor volume and uptake were measured as 87 ml and 7781 KBq/ml.
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healthcare, QC, Canada). Immediately after injection, a 1-h PET scan was performed using the Tri-
umph® LabPET8/CT/SPECT system (GE Healthcare, Waukesha, USA). After data acquisition, PET data
were reconstructed with the maximum a posteriori (MAP) reconstruction algorithm. The pixel size
was 0.866  0.866  0.796 mm and in the center ﬁeld of view the resolution was 1.4 mm full-width-
at-half-maximum. Following the microPET scan, a 10-min CT scan was performed with the following
parameter settings: 360 rotation steps, tube voltage 80 kV, tube current 500 mA, binning 4, and
exposure time 310 ms. The pixel size was 0.091  0.091  0.091 mm. MicroPET/CT images were fused
using the OsiriX imaging analysis software developed at the CIBM platform of the Geneva University
Medical Center. Before fusion region of interests (ROIs) were drawn on the PET pictures manually by
qualitative assessment covering the whole tumor and subsequently tumor volume and tracer uptake,
assessed by standard uptake values (SUV) mean and maximum, were generated by summation of
voxels within the tomographic planes. Another study was recently published, which conﬁrms the
feasibility of microPET/CT imaging in human gliobastoma xenografted CAM, using different PET
tracers [28].
3. Overall value of the CAM
Novel anticancer treatments are mostly evaluated in tumor-bearing mice using a tumor growth
delay assay or different imaging technologies prior to passage in clinical trials. However, establishment
of experimental parameters, such as the treatment schedule (i.e. type, route, dose and timing), is an
expensive, time-consuming and tedious process that requires, as a prerequisite, ethics committee
approval for animal experimentation. To date, the CAM model was not an optimal alternative due to
several drawbacks, especially poor tumor size homogeneity and only 2-D tumor measurement on the
CAM surface. Improving the CAM model by using tumor spheroid grafting and microPET/CT would
provide a simple, reliable, reproducible and quantitative method for obtaining doseeresponse analysis
and estimating the treatment schedule (i.e. type, route, dose and timing) before initiating clinical trials.
This method is particularly suitable for evaluating rapidly the effect of nutritional therapies on tumor
development, growth, vascularization and metastasis. Although experimentation in the CAMmodel is
probably not sufﬁcient for in-depth evaluation of long-term treatment related side effects and toxicity
on healthy organs and tissues, it may contribute to implement the 3R principle (Reduce, Reﬁne,
Replace) by reducing the number of animal suffering and sacriﬁce.
4. Conclusion
The use of tumor spheroid grafting andmicroPET/CT imaging in the CAMmodelmay provide a rapid
and low-cost alternative to avoid animal suffering and sacriﬁce for testing nutritional therapy in cancer
research.
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